, Columnist
PARP Wars: Biotech M&A's New Hope
Tesaro and Clovis make particularly appealing targets.
This article is for subscribers only.
It's a recipe for ending biopharma's slow year for deals1473799973422 that almost looks designed in a lab.
Cancer drugs known as PARP inhibitors have major upside sales potential. There are two potentially acquirable makers of such drugs in Tesaro and Clovis, which recently saw shares jump due to potential interest from Gilead. Both their medicines are rushing toward approval just as a number of companies are getting hungry to buy a cancer-drugmaker.